Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
2011 · Journal of Experimental & Clinical Cancer Research · 60 citations
https://doi.org/10.1186/1756-9966-30-8
H
Huanling Zhu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
146
Papers
1.2K
Citations
18
h-index
23
i10-index
Huanling Zhu is an academic researcher from Sichuan University. The author has contributed to research in topics: Chronic Myeloid Leukemia Treatments & Chronic Lymphocytic Leukemia Research & Myeloproliferative Neoplasms: Diagnosis and Treatment. The author has an h-index of 18, co-authored 125 publications.
ORCID: 0000-0002-5226-3828Papers by this author
worksDasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
2020 · Leukemia · 56 citations
https://doi.org/10.1038/s41375-020-0805-1
Antiproliferative and Apoptosis Triggering Potential of Paclitaxel-Based Targeted-Lipid Nanoparticles with Enhanced Cellular Internalization by Transferrin Receptors—a Study in Leukemia Cells
2018 · Nanoscale Research Letters · 17 citations
https://doi.org/10.1186/s11671-018-2688-x
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
2024 · Journal of Cancer Research and Clinical Oncology · 4 citations
https://doi.org/10.1007/s00432-024-05700-x
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
2024 · Blood Cancer Journal · 1 citations
https://doi.org/10.1038/s41408-024-01202-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat